Ting Wu
Welcome,         Profile    Billing    Logout  
 3 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wu, Ting
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
NCT04704908: Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)

Active, not recruiting
N/A
979
RoW
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli), There is no other Intervention in this study
Jun Zhang, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Persistent Infection
04/21
12/23
NCT04969445: The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Recruiting
N/A
647
RoW
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli), There is no other Intervention in this study
Jun Zhang, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Persistent Infection
07/23
01/24
NCT05045755: The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Recruiting
N/A
1339
RoW
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli), There is no other Intervention in this study
Jun Zhang, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Persistent Infection
08/23
01/24
HPV-PRO-006-4, NCT06243666: Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Not yet recruiting
N/A
2188
RoW
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli), No intervention
Xiamen University, Xiamen Innovax Biotech Co., Ltd, Center for Disease Control and Prevention, Sheyang County, Yancheng City, Jiangsu Province, China
Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection
12/26
12/26

Download Options